Efficacy of the first-generation MDM2 antagonist Nutlin-3a in cancers such as liposarcomas that express MDM2-B has been investigated, however, responses were heterogeneous with no promising results of Nutlin3a treatment achieved in MDM2-B expressing liposarcomas [124]. Here, MDM2 is linked to liposarcoma.